GT Biopharma, Inc.
GTBP
$0.43
-$0.01-1.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.95M | 6.56M | 6.11M | 7.09M | 8.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.42M | 10.59M | 10.81M | 13.21M | 14.36M |
| Operating Income | -12.42M | -10.59M | -10.81M | -13.21M | -14.36M |
| Income Before Tax | -28.35M | -9.10M | -9.40M | -11.67M | -13.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.35 | -9.10 | -9.40 | -11.67 | -13.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.35M | -9.10M | -9.40M | -11.67M | -13.16M |
| EBIT | -12.42M | -10.59M | -10.81M | -13.21M | -14.36M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.93 | -3.38 | -4.08 | -5.70 | -7.01 |
| Normalized Basic EPS | -2.40 | -2.33 | -2.80 | -3.83 | -4.38 |
| EPS Diluted | -3.93 | -3.38 | -4.08 | -5.70 | -7.01 |
| Normalized Diluted EPS | -2.40 | -2.33 | -2.80 | -3.83 | -4.38 |
| Average Basic Shares Outstanding | 22.04M | 11.32M | 9.61M | 8.55M | 7.58M |
| Average Diluted Shares Outstanding | 22.04M | 11.32M | 9.61M | 8.55M | 7.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.81% | -0.93% | -- | -- | -- |